Related Tags >> Novartis GlaxoSmithKline cystic fibrosis milestones

COPD News

Most Popular COPD Story

PhRMA's COPD pipeline report spotlights blockbuster hopefuls

February 6, 2012 — 10:37am ET | By John Carroll

Anyone looking for a basic primer on experimental COPD drugs should check out PhRMA's latest compilation of new drugs in the pipeline. The big trade group found 54 COPD studies underway, which Read more...

COPD Press Releases

Latest Headlines

PhRMA's COPD pipeline report spotlights blockbuster hopefuls
February 6, 2012
Theravance shares tank on troubling study results for Relovair
January 9, 2012
Biotechs round up new venture cash for COPD, Alzheimer's programs
January 4, 2012
Novartis signals serious U.S. delay for blockbuster COPD program
October 25, 2011
Amira spins out programs with $475M BMS buyout
September 9, 2011
Pulmatrix reels in $14M for its work on COPD, cystic fibrosis
August 15, 2011
Novartis wins FDA OK of low-dose COPD therapy
July 5, 2011
Novartis unveils more promising Ph3 data on COPD program
June 30, 2011
GSK, Theravance report Ph3 successes for COPD treatment
June 2, 2011
Pearl's combo COPD treatment beats market rivals as it races to Ph3
May 18, 2011
Novartis delivers promising Ph3 data for combo COPD treatment
May 16, 2011
Novartis' Ph3 success advances blockbuster COPD program
April 19, 2011
FDA experts turn thumbs down on Novartis's high-dose COPD drug
March 9, 2011
Novartis's megablockbuster COPD program faces key hurdle
March 2, 2011
Forest, Nycomed win narrow FDA approval on new COPD drug
March 1, 2011
Forest's COPD drug bounces back with positive Ph3
January 5, 2011
Roche adds $201M in milestones to Galapagos R&D pact
May 11, 2010
Garner crafts $30M Series A to lift Elevation Pharma
January 21, 2010
Galapagos, Roche enter $588.7M COPD alliance
January 11, 2010
Novartis hit with FDA delay on blockbuster COPD drug
October 19, 2009

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events